Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunesis secures European patent covering Vosaroxin
Vosaroxin, formerly known as voreloxin, is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer.
Vosaroxin, formerly known as voreloxin, is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer.
The preliminary Phase I results for the EV71 vaccine in adults showed a good safety profile and preliminary immunogenicity profile. Sinovac subsequently initiated the inoculations in the young
The double-blind, randomized, placebo-controlled Phase 2a study of VX-765 enrolled 60 people with treatment-resistant partial onset epilepsy. The primary endpoint of the study was safety and tolerability, and
With this approval, Herceptin is now available for patients with HER2-positive advanced or recurrent gastric cancer and HER2-positive breast cancer (advanced or recurrent / postoperative adjuvant chemotherapy) in
The branded generics and OTC product portfolio of PharmaSwiss is expected to strengthen Valeant’s presence in the region. Reportedly, the senior management team of PharmaSwiss will remain with
As per the terms of the agreement, Epizyme is entitled to get an upfront payment including research, development and sales milestones and royalties to Eisai as the project
Talon claims Marqibo is a novel, targeted Optisome encapsulated formulation product candidate of the FDA-approved anticancer drug Vincristine. The company is developing Marqibo as a treatment for Ph-
Zidovudine tablets are used in conjunction with other medications for controlling HIV infection and are also indicated for the prevention of mother-to-child HIV-1 transmission. The product is included
ACT said that this opinion will now be forwarded by the EMA to the European Commission for their adoption, which should follow in coming weeks. ACT’s interim chairman
The study recruited and dosed people who did not benefit from the use of at least two currently available medicines for partial epilepsy. In the study, the patients